Literature DB >> 24993182

Lower urinary tract and sexual dysfunction in neurological patients.

David B Vodušek1.   

Abstract

BACKGROUND: Lower urinary tract dysfunction (LUTD) and sexual dysfunction (SD) are common in neurological patients due to a combination of lesions affecting relevant neural control, constraints imposed by sensorimotor and cognitive deficits and--particularly for SD--psychosocial consequences of chronic neurological disease.
SUMMARY: This review summarizes the etiology, diagnosis and treatment of LUTD and SD in neurological patients. KEY MESSAGES: LUTD may lead to serious health problems; both LUTD and SD significantly affect quality of life. Management of patients with spinal cord injury and dysraphism is undertaken in specialized centers according to established guidelines. Treatment of neurological patients with noncomplicated neurogenic LUTD or SD should preferentially be guided by a neurologist. CLINICAL IMPACT: For rational treatment of urinary symptoms, an accurate assessment is mandatory; the bladder and the sphincter need to be defined as normal, over- or underactive. Urodynamic testing is the gold standard for functional diagnosis; assessment of residual urine and uroflow are the minimal requirements before considering management. Dysfunction of desire, arousal and orgasm (ejaculation) may be diagnosed by medical history and are amenable to counselling and treatment, which is--in the case of erectile dysfunction--evidence based. Further high-quality studies are necessary to test the best approaches for diagnosing and managing particular types of neurogenic LUTD and SD in the different neurological patient populations.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 24993182     DOI: 10.1159/000360529

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  1 in total

Review 1.  Exploring Host-Pathogen Interactions through Biological Control.

Authors:  Francesca Di Giallonardo; Edward C Holmes
Journal:  PLoS Pathog       Date:  2015-06-25       Impact factor: 6.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.